Physician profile
Michael Chandler
NPI 1205937521
$1,274.37
in general payments reported to CMS, 2019-2025
21 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $65.30 · 2021: $169 · 2022: $286 · 2023: $168 · 2024: $242 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $231.34 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $168.83 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $143.83 | 2022-2025 | Airsupra |
| Glaxosmithkline, LLC. | $126.87 | 2019-2022 | |
| Novo Nordisk INC | $98.24 | 2021-2024 | Rybelsus, Ozempic |
| Insulet Corporation | $79.97 | 2019 | |
| Corcept Therapeutics | $60.95 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.99 | 2021-2023 | Tradjenta, Jardiance |
| Pfizer INC. | $47.94 | 2022-2024 | |
| Abbvie INC. | $32.41 | 2022 | |
| Edwards Lifesciences Corporation | $30.18 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $29.30 | 2019-2020 | |
| Mannkind Corporation | $24.48 | 2022 | |
| Dexcom, INC. | $23.31 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.06 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.60 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $18.24 | 2025 | Cologuard Collection Kit |
| Shire North American Group INC | $18.10 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.20 | 2025 | Caplyta |
| Indivior INC. | $14.85 | 2025 | Sublocade |
| Amarin Pharma, INC. | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.